Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
146.57
-3.04 (-2.03%)
At close: Oct 10, 2025, 4:00 PM EDT
147.00
+0.43 (0.29%)
After-hours: Oct 10, 2025, 6:03 PM EDT
Biogen Revenue
Biogen had revenue of $2.65B in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $9.86B, up 2.14% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.86B
Revenue Growth
+2.14%
P/S Ratio
2.19
Revenue / Employee
$1,314,530
Employees
7,605
Market Cap
21.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BIIB News
- 1 day ago - Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - GlobeNewsWire
- 1 day ago - Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 1 day ago - Biogen's Comeback: Why The Bulls Are Finally Winning Again - Seeking Alpha
- 4 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PRNewsWire
- 4 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 7 days ago - BIIB Stock: Is Biogen Still A Buy After The 14% Spike? - Forbes
- 11 days ago - “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China - GlobeNewsWire
- 16 days ago - Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha